Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M.
Yoshikawa T, et al. Among authors: hato s.
Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22.
Lancet Gastroenterol Hepatol. 2019.
PMID: 30679107
Clinical Trial.